A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)

Conclusion: No safety issues were revealed with either basal insulin. Due to the low number of patients recruited, no efficacy conclusions could be drawn.ClinicalTrials.govidentifier: NCT02131272.What is known:• There is a growing worldwide epidemic of type 2 diabetes in children and adolescents.• There is a lack of research and limited treatment options currently available in this population.What is new:• No safety issues with insulin detemir or neutral protamine Hagedorn insulin in children and adolescents with type 2 diabetes were observed.• Improving clinical trial recruitment, along with providing early, efficacious, and safe treatment options, in this population is critical.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research